Colon cancer

Byaibio

Colon cancer is a malignant disease of the colon and is being studied both as a disease model and as a therapeutic target, with one proposed strategy being triple therapy for improved control. Mechanistically, recent work highlights cordycepin-enhanced ctla 4 blockade, microbiome-mediated immunomodulation via eubacterium rectale, and engineered probiotic/immune combinations that activate the STING pathway to boost anti-tumor immunity. It is also linked to stage III dMMR disease, where ctDNA-guided de-escalation and adjuvant atezolizumab plus chemotherapy have been evaluated, and to Lynch syndrome-associated immune checkpoint inhibitor resistance. Additional literature describes modified banxia xiexin decoction as an anti-cancer intervention that promotes mitochondrial fission by inhibiting the CHD6-TMEM65 axis in colon cancer cells.

Immunotherapy and microbiome modulation

  • A 2026 International Immunopharmacology study showed that cordycepin combined with ctla 4 inhibitors significantly improved antitumor efficacy in colon cancer through eubacterium rectale-mediated immunomodulation (PMID:41722537).
  • The same study supports microbiome-linked enhancement of checkpoint blockade, identifying eubacterium rectale as a contributor to therapeutic response in colon cancer (PMID:41722537).
  • A 2026 Biomaterials paper reported that methionine-depleting engineered probiotics promoted PD-L1 antibody immunotherapy by activating the STING pathway in colon cancer models (PMID:41604978).
  • Immune checkpoint inhibitor resistance was documented in a Lynch syndrome-associated colon cancer case report, underscoring a clinically relevant resistance phenotype (PMID:42026473).

Chemotherapy, adjuvant therapy, and biomarker-guided management

  • ctDNA-guided de-escalation was evaluated in DYNAMIC-III for stage III colon cancer, reflecting biomarker-informed treatment tailoring (PMID not provided in summary; relation only).
  • ATOMIC supported adjuvant atezolizumab plus chemotherapy in stage III dMMR colon cancer, indicating benefit in a molecularly defined subgroup (PMID not provided in summary; relation only).
  • Colon cancer is explicitly described as the disease context for a case report involving dMMR high-grade intraepithelial neoplasia with Lynch syndrome-associated disease (PMID:42026473).
  • The entry’s key facts indicate colon cancer is being used as both a disease model and a therapeutic target, with triple therapy proposed as a strategy.

Traditional medicine and cellular mechanisms

  • A 2026 Journal of Ethnopharmacology study found that modified banxia xiexin decoction promoted mitochondrial fission in colon cancer cells by inhibiting the CHD6-TMEM65 axis (PMID:41663003).
  • This supports an anti-cancer mechanism for modified banxia xiexin decoction in colon cancer, extending traditional medicine research into defined molecular pathways (PMID:41663003).
  • The same report links the intervention to altered mitochondrial dynamics, a mechanistic hallmark relevant to tumor cell survival and metabolism (PMID:41663003).